Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center
| Autor: | Gerges Attia Demian, Heba El-Sayed Eissa, Salah Fayaz |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Adjuvant systemic treatment Cancer Research Receptor ErbB-2 medicine.medical_treatment Estrogen receptor Disease 0302 clinical medicine Cancer control Oncotype DX recurrence score Medicine 030212 general & internal medicine Breast Stage (cooking) Mastectomy medicine.diagnostic_test Early breast cancer Age Factors Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Kuwait Receptors Estrogen Chemotherapy Adjuvant 030220 oncology & carcinogenesis 21 gene recurrence score Female Oncotype DX Adjuvant Adult medicine.medical_specialty Clinical Decision-Making Breast Neoplasms lcsh:RC254-282 Risk Assessment 03 medical and health sciences Breast cancer McNemar's test Internal medicine parasitic diseases Biomarkers Tumor Humans Aged business.industry Gene Expression Profiling medicine.disease Feasibility Studies Treatment decision making Neoplasm Recurrence Local business Follow-Up Studies |
| Zdroj: | Journal of the Egyptian National Cancer Institute, Vol 32, Iss 1, Pp 1-7 (2020) |
| ISSN: | 2589-0409 |
| Popis: | Background The Oncotype DX is a quantitative assay of the expression of 16 tumor-related genes and 5 reference genes that predicts the potential of adjuvant chemotherapy benefit in estrogen receptor (ER)-positive early breast cancer patients. The study aims to evaluate the impact of Oncotype DX as a tool for adjuvant treatment decision of ER-positive, HER2-negative, N0/N1 early-stage breast cancer patients and to determine which clinicopathological criteria derived the greatest advantage. Results A hundred patients at a median age of 50 years were included. TNM stage distribution was 34, 63, and 3 patients for stages I, II, and IIIA respectively. Fifty-four patients had luminal A and 46 had luminal B tumors. The recurrence score (RS) results were low, intermediate, and high risk in 54, 34, and 12 patients respectively. Before the test results, adjuvant chemoendocrine therapy (CET) was recommended for 46 patients while 54 were advised for endocrine therapy (ET). After getting the test results, 25 patients received CET (1, 12, and12 patients in the low-, intermediate-, and high-risk groups respectively) and 75 received ET. Treatment change was documented in 37 patients (8 patients from ET to CET and 29 from CET to ET; p = 0.001, McNemar test). Treatment change was significant among patients ≤ 50 years, luminal B tumors, stage II and IIIA disease, and node-positive disease. Conclusion Oncotype DX testing resulted in significant changes in the adjuvant treatment decisions in ER-positive, HER2-negative early breast cancer particularly in the case of young, luminal B, N1, and stage II–IIIA disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|